Prokidney Corp. (PROK): Depreciation & Amortization
$6.58M
Year ended 2025-12-31
$6.85M
Trailing 12 months to 2026-06-30
+29.4%
3-year compound annual growth
+46.8%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.58M | +21.0% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $5.43M | +41.0% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $3.85M | +26.9% | 2026-03-18, From 2023-01-01 |
| 2022-12-31 | $3.04M | +53.0% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $1.98M | +105.8% | 2024-03-22, From 2021-01-01 |
| 2020-12-31 | $964.0K | n/a | 2023-03-28, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Prokidney Corp. (PROK) | 2025-12-31 | $6.58M | +21.0% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $400.0K | -63.6% |
| Pluri Inc. (PLUR) | 2026-06-30 | $511.0K | +61.7% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $2.48M | +8.7% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.42M | -13.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $364.0K | -9.9% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $117.1K | +2.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $537.0K | -62.8% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $19.48M | +1.1% |
Compare PROK, IMA, PLUR, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗